159 related articles for article (PubMed ID: 22114706)
1. Adherence to highly active antiretroviral treatment in HIV-infected Rwandan women.
Musiime S; Muhairwe F; Rutagengwa A; Mutimura E; Anastos K; Hoover DR; Qiuhu S; Munyazesa E; Emile I; Uwineza A; Cowan E
PLoS One; 2011; 6(11):e27832. PubMed ID: 22114706
[TBL] [Abstract][Full Text] [Related]
2. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
3. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
4. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
5. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
[TBL] [Abstract][Full Text] [Related]
6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
7. Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa.
Huet C; Ouedraogo A; Konaté I; Traore I; Rouet F; Kaboré A; Sanon A; Mayaud P; Van de Perre P; Nagot N
BMC Public Health; 2011 Sep; 11():700. PubMed ID: 21917177
[TBL] [Abstract][Full Text] [Related]
8. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes.
Chung MH; Richardson BA; Tapia K; Benki-Nugent S; Kiarie JN; Simoni JM; Overbaugh J; Attwa M; John-Stewart GC
PLoS Med; 2011 Mar; 8(3):e1000422. PubMed ID: 21390262
[TBL] [Abstract][Full Text] [Related]
10. Association of pre-treatment nutritional status with change in CD4 count after antiretroviral therapy at 6, 12, and 24 months in Rwandan women.
Kiefer E; Hoover DR; Shi Q; Dusingize JC; Cohen M; Mutimura E; Anastos K
PLoS One; 2011; 6(12):e29625. PubMed ID: 22216334
[TBL] [Abstract][Full Text] [Related]
11. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model.
Chu H; Gange SJ; Yamashita TE; Hoover DR; Chmiel JS; Margolick JB; Jacobson LP
Am J Epidemiol; 2005 Oct; 162(8):787-97. PubMed ID: 16135508
[TBL] [Abstract][Full Text] [Related]
12. Short-term garlic supplementation and highly active antiretroviral treatment adherence, CD4+ cell counts, and human immunodeficiency virus viral load.
Liu C; Wang C; Robison E; Levine AM; Gandhi M; Schwartz R; Weber KM; Merenstein D
Altern Ther Health Med; 2012; 18(1):18-22. PubMed ID: 22516847
[TBL] [Abstract][Full Text] [Related]
13. High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda.
Elul B; Basinga P; Nuwagaba-Biribonwoha H; Saito S; Horowitz D; Nash D; Mugabo J; Mugisha V; Rugigana E; Nkunda R; Asiimwe A
PLoS One; 2013; 8(1):e53586. PubMed ID: 23326462
[TBL] [Abstract][Full Text] [Related]
14. An investigation of the possible interaction between the use of Vitamin C and highly active antiretroviral therapy (HAART) adherence and effectiveness in treated HIV+ women.
Merenstein D; Wang C; Gandhi M; Robison E; Levine AM; Schwartz RM; Weber KM; Liu C
Complement Ther Med; 2012 Aug; 20(4):222-7. PubMed ID: 22579434
[TBL] [Abstract][Full Text] [Related]
15. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach.
Spire B; Duran S; Souville M; Leport C; Raffi F; Moatti JP;
Soc Sci Med; 2002 May; 54(10):1481-96. PubMed ID: 12061483
[TBL] [Abstract][Full Text] [Related]
16. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
[TBL] [Abstract][Full Text] [Related]
17. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
18. Patient-level outcomes and virologic suppression rates in HIV-infected patients receiving antiretroviral therapy in Rwanda.
Riedel DJ; Stafford KA; Memiah P; Coker M; Baribwira C; Sebeza J; Karorero E; Nsanzimana S; Morales F; Redfield RR
Int J STD AIDS; 2018 Aug; 29(9):861-872. PubMed ID: 29621951
[TBL] [Abstract][Full Text] [Related]
19. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART.
Guaraldi G; Murri R; Orlando G; Orlandi E; Sterrantino G; Borderi M; Grosso C; Cattelan AM; Nardini G; Beghetto B; Antinori A; Esposito R; Wu AW
HIV Clin Trials; 2003; 4(2):99-106. PubMed ID: 12671777
[TBL] [Abstract][Full Text] [Related]
20. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
